(Total Views: 596)
Posted On: 08/26/2021 5:17:55 PM
Post# of 157634
“Dr. Srinivasan provides 30 years of broad regulatory and drug development experience including a career serving as Director of CMC Regulatory Affairs for Regeneron Pharmaceuticals, Inc. where he led the CMC strategy and successfully submitted a monoclonal antibody based BLA (Dupixent approved in 2017) “
Now we have something to talk about.
Now we have something to talk about.
(2)
(0)
Federal Whistleblower
Case References
• HHS & SEC Whistleblower: HL-1412396
• DOJ Investigation Report / Whistleblower ID: 20250705-0001
• NIH Case Reference: CS1137565
• DoD Case: 16282
• IC IG / 50 U.S.C. §3033 / ARPA-H (Advanced Research Projects Agency for Health)
Founder & CEO
FireGate BioTech | AI Lux Veritas™
Contact FireGate Biotech
https://img1.wsimg.com/blobby/go/05a949a0-169...5_FULL.pdf
Case References
• HHS & SEC Whistleblower: HL-1412396
• DOJ Investigation Report / Whistleblower ID: 20250705-0001
• NIH Case Reference: CS1137565
• DoD Case: 16282
• IC IG / 50 U.S.C. §3033 / ARPA-H (Advanced Research Projects Agency for Health)
Founder & CEO
FireGate BioTech | AI Lux Veritas™
Contact FireGate Biotech
https://img1.wsimg.com/blobby/go/05a949a0-169...5_FULL.pdf
